research‎ > ‎

ViaCyte

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

An Outline of This Clinical Trial

This is a research study testing a possible new treatment for Type 1 diabetes called VC-01 combination product.  The product consists of two parts:  pancreatic endoderm cells (from human embryonic stem cells), called PEC-01™ cells, and a retrievable encapsulation device known as the Encaptra drug delivery system.  VC-01 is expected to control blood glucose as a “replacement pancreas” producing insulin after it is surgically placed under the skin.  It is estimated this may take several months to work. Your other insulin doses will continue to be used as prescribed.  Study staff will monitor your diabetes, blood sugar values, and any hypoglycemia (low blood sugar) throughout your participation and adjust your insulin doses when needed.

If you participate in the study, you will be assigned to receive a select number of VC-01 units implanted during the study. Your smaller VC-01 units will be removed at various points in the study, but the larger units will not be removed until the end of the study. This study will last approximately 2 years and includes about 19 visits to the study clinic (including initial screening visits).

Patient Eligibility

You may be eligible for this study if you are an adult (between the ages of 18 and 55 years old), have been diagnosed with Type 1 diabetes for a minimum of 3 years, and have a stable, optimized diabetic regimen for at least 3 months.

Comments